The MPN Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The MPN Channel on VJHemOnc is supported by Constellation Pharmaceuticals, Kartos Therapeutics, Inc. and Sierra Oncology. These supporters have no influence over the production of the content.

Latest Videos The MPN Sessions Podcasts e-Learning Presentations Subtypes Conferences Features Expert Editorial Board

Welcome to The Myeloproliferative Neoplasms (MPN) Channel

VJHemOnc brings you the newest developments in MPNs, including highly anticipated clinical research data, as well as cutting-edge diagnostic and treatment approaches presented at major international congresses. Also explore the latest clonal evolution discoveries, emerging therapies, and novel drug combinations, all in the form of exclusive video interviews, podcasts and roundtable discussions.

Subtypes

Essential Thrombocythemia
Myelofibrosis
Polycythemia Vera
Systemic Mastocytosis
Chronic Myelomonocytic Leukemia
3:35
Analysis from MOST: disease progression and leukemic transformation in lower-risk myelofibrosis
Rami Komrokji • 19 Dec 2022
1:43
Updates from a Phase II study of bomedemstat for the treatment of essential thrombocythemia
Harinder Gill • 10 Dec 2022
1:25
Exciting updates in essential thrombocythemia: exploring novel agents
Harinder Gill • 10 Dec 2022
3:21
The current standard of care for patients with essential thrombocythemia
Harinder Gill • 10 Dec 2022
View All Videos
3:35
Analysis from MOST: disease progression and leukemic transformation in lower-risk myelofibrosis
Rami Komrokji • 19 Dec 2022
3:12
Prolonged & continuous transfusion independence after imetelstat treatment in the IMerge trial
Rami Komrokji • 19 Dec 2022
3:22
Phase I dose-escalation study of zelavespib in patients with relapsed myelofibrosis
Gary Schiller • 1 Dec 2022
2:40
Safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis
Harinder Gill • 10 Dec 2022
View All Videos
1:56
Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera
Srdan Verstovsek • 7 Dec 2022
2:55
PV-AIM: using machine learning to predict resistance to hydroxyurea therapy in patients with PV
Srdan Verstovsek • 7 Dec 2022
3:06
Results from the MAJIC-PV trial: ruxolitinib vs BAT for hydroxyurea resistant/intolerant PV
Claire Harrison • 12 Dec 2022
4:31
Driver mutations in MPNs and their impact on prognosis: JAK2, MPL, and CALR
Prithviraj Bose • 28 Nov 2022
View All Videos
1:27
Ongoing trials and novel agents being explored in advanced and indolent systemic mastocytosis
Deepti Radia • 30 Aug 2022
1:46
Unmet needs and challenges in advanced systemic mastocytosis
Deepti Radia • 30 Aug 2022
2:03
The safety and efficacy of avapritinib in patients with advanced systemic mastocytosis
Deepti Radia • 30 Aug 2022
2:56
Insights into the treatment and management of advanced systemic mastocytosis
Deepti Radia • 30 Aug 2022
View All Videos
1:32
Phase II efficacy and safety results of ruxolitinib for patients with symptomatic CMML
Eric Padron • 9 Dec 2022
1:08
An insight into the mutational landscape and unique features of CMML
Eric Padron • 26 Aug 2022
1:26
The challenges of treating rare overlap syndromes and strategies to overcome these
Eric Padron • 26 Aug 2022
0:53
An insight into ongoing trials in CMML
Eric Padron • 26 Aug 2022
View All Videos

Conferences

ASH 2022
MPN Congress 2022
SOHO 2022
Texas MPN Workshop 2022
EHA 2022
ASCO 2022
3:35
Analysis from MOST: disease progression and leukemic transformation in lower-risk myelofibrosis
Rami Komrokji • 19 Dec 2022
3:12
Prolonged & continuous transfusion independence after imetelstat treatment in the IMerge trial
Rami Komrokji • 19 Dec 2022
3:22
Phase I dose-escalation study of zelavespib in patients with relapsed myelofibrosis
Gary Schiller • 1 Dec 2022
1:43
Updates from a Phase II study of bomedemstat for the treatment of essential thrombocythemia
Harinder Gill • 10 Dec 2022
View All Videos
5:04
Latest advances in treatment strategies for hypereosinophilic syndromes & challenges in this field
Amy Klion • 7 Nov 2022
Fibrotic progression of ET and PV: clinical and biological considerations
Raajit Rampal • 7 Nov 2022
Dynamic personalized thrombosis prediction in polycythemia vera
Ghaith Abu-Zeinah • 7 Nov 2022
Polycythemia vera: myths, mechanisms, and management
Jerry Spivak • 7 Nov 2022
View All Videos
1:54
The potential role of cellular therapies and vaccines in the future treatment of MPNs
Srdan Verstovsek • 28 Sep 2022
1:29
The current role of allogeneic transplantation in MF
Haris Ali • 5 Oct 2022
1:15
The safety and efficacy of peritransplantation ruxolitinib in patients with MF
Haris Ali • 5 Oct 2022
3:00
The promise of momelotinib in the treatment of myelofibrosis
Prithviraj Bose • 30 Sep 2022
View All Videos
COVID-19 and MPNs: updates from the ELN study
Tiziano Barbui • 30 Sep 2022
Clinical risk factors for disease progression in MPNs
Andrew Kuykendall • 30 Sep 2022
Thrombosis and COVID-19 in MPN patients
Valerio De Stefano • 30 Sep 2022
Mitigating COVID-19 infection risk for MPN patients
Laura Michaelis • 30 Sep 2022
View All Videos
1:44
Emerging novel agents for the treatment of mastocytosis
Tracy George • 12 Jun 2022
1:56
The impact of SF3B1 mutations in myelofibrosis
Jayastu Senapati • 13 Jun 2022
2:13
The future of MPN treatment: exciting agents and targets being investigated
Srdan Verstovsek • 22 Jun 2022
1:49
Unmet needs and challenges in mastocytosis
Tracy George • 12 Jun 2022
View All Videos
3:19
Therapeutic options following failure to JAK inhibitors
Ciro Rinaldi • 6 Jun 2022
1:20
MPNs at ASCO 2022: cytopenic myelofibrosis, non-JAK inhibitor approaches & combination therapy
Ciro Rinaldi • 6 Jun 2022
2:00
Expression of CD47 and CALR in MPNs
Ciro Rinaldi • 6 Jun 2022
1:08
Key takeaways in hemonc at ASCO 2022
Naveen Pemmaraju • 5 Jun 2022
View All Videos

The MPN Channel on VJHemOnc is supported by Constellation Pharmaceuticals, Kartos Therapeutics, Inc. and Sierra Oncology.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The MPN Channel, please contact us.

VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals